It is well established that by introducing the cell-adhesive sequence Arg-Gly-Asp (RGD) from fibronectin into Bombyx mori silk fibroin by covalent coupling or bioengineering techniques, excellent ...

Today, genomics is saving countless lives and even entire species, thanks in large part to a commitment to collaborative and ...

This article investigates the challenge of enabling multifinger hands to perform human-like functional grasping for various intentions. However, accomplishing functional grasping in real robot hands ...

This innovative software, CRISPRware, optimizes guide RNA design for genome editing, supporting research on genetic disorders ...

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...

Point cloud sequence-based 3D action recognition has achieved impressive performance and efficiency. However, existing point cloud sequence modeling methods cannot adequately balance the precision of ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

glucagon-like peptide-1 receptor insulinoma exendin-4 68 Ga 99m Tc Over the last 15 y, peptide receptor targeting of cancer cells with radiolabeled peptides has become an important method for the ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying. Aims: To assess ...

Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection ...